Galenika: Record Number of New Products in 2021
09/10/2021 • Customer news
During the first seven months of this year, Galenika achieved a significant expansion of its product portfolio, growth in Serbia and regional markets, and further modernization of operations. Galenika shows constant growth in all segments of its business in 2021.
In the period from January to July, Galenika achieved a 16% increase in production compared to the same period last year. Since the beginning of the year, the company has registered as many as 12 new products in Serbia, while 11 products have been launched on the market so far. Galenika records an increase in sales in the region, and by the end of July 2021, five products have been launched on the markets of Bosnia and Herzegovina, Montenegro and Northern Macedonia, and another 9 are planned to be launched by the end of the year. In the EU market, Galenika has registered one product, and the registration of another 20 products is planned. Galenika's Institute for Research and Development, in strategic partnership with its sister company from Brazil - EMS, is working on the technology transfer of five products from the newer generation of generic drugs.
In the period January-July 2021, Galenika achieved an increase in sales by 13 percent compared to the same period last year, which further strengthened the company in the stable second position in terms of share in the pharmaceutical market of Serbia. Exports to the countries of the region (Bosnia and Herzegovina, Montenegro, North Macedonia) increased by as much as 51 percent, while sales on international markets outside the region (Europe, Middle East, Africa) is more than doubled.
For more information, visit the link.